EHMT2 and Familial prostate cancer: G9a, a histone methyltransferase that catalyzes H3K9me2, can be targeted with the newly developed dual G9a/DNMT inhibitor, CM-272, described to decrease H3K9me2 and m5C levels in bladder and prostate cancer cells (95, 143).